Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exploiting the RNA interference pathway to counter hepatitis B virus replication.

Patrick Arbuthnot1, Sergio Carmona, Abdullah Ely

  • 1Hepatitis B Virus Research Programme, Department of Molecular Medicine and Haematology, University of the Witwatersrand, Private Bag 3, Wits 2050, South Africa. arbuthnotpb@pathology.wits.ac.za

Liver International : Official Journal of the International Association for the Study of the Liver
|February 9, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The strategic importance of mRNA vaccine technologies in Africa for achieving public health independence.

Communications medicine·2026
Same author

Three-dimensional culture models of hepatitis B virus infection: Progress, challenges, and opportunities.

Virology·2026
Same author

Sociodemographic and health-related factors associated with viral load non-suppression and body mass index in adults with depression symptoms receiving antiretroviral therapy in South Africa.

PloS one·2026
Same author

Structural mimics of SARS-CoV-2.

Infection·2026
Same author

Erratum: Time to Include Vestibular Neurology as a Core Competency for Neurology Trainees.

Neurology. Education·2025
Same author

Time to Include Vestibular Neurology as a Core Competency for Neurology Trainees.

Neurology. Education·2025

Hepatitis B virus (HBV) infection can be targeted using RNA interference (RNAi) therapies. Small interfering RNA (siRNA) shows promise for inhibiting HBV replication, offering a novel treatment strategy.

Area of Science:

  • Molecular Biology
  • Virology
  • Hepatology

Background:

  • Chronic Hepatitis B Virus (HBV) infection is a significant global health issue, particularly in sub-Saharan Africa and Asia.
  • HBV infection is linked to severe liver diseases, including cirrhosis and hepatocellular carcinoma (HCC).
  • Current therapies for HBV are only partially effective, highlighting the need for novel treatment approaches.

Purpose of the Study:

  • To explore the potential of RNA interference (RNAi) as a novel therapeutic strategy against HBV infection.
  • To investigate the use of small interfering RNA (siRNA) for sequence-specific degradation of HBV RNA.
  • To assess the feasibility of targeting the compact HBV genome, which is amenable to nucleic acid hybridization therapies.

Main Methods:

  • Utilizing the RNA interference (RNAi) pathway for targeted RNA degradation.

Related Experiment Videos

  • Employing synthetic small interfering RNA (siRNA) duplexes and Pol III-derived short hairpin RNA (shRNA) sequences.
  • Conducting in vitro and in vivo studies to evaluate the inhibition of HBV replication.

    • Main Results:

    • Demonstrated that synthetic siRNA and shRNA sequences can inhibit HBV replication in transfected cells.
    • Observed significant variation in the effectiveness of different anti-HBV RNAi sequences.
    • Identified that efficacy is likely influenced by the activation of the RNAi pathway by specific siRNA species.

    Conclusions:

    • RNA interference (RNAi) presents a promising therapeutic avenue for treating chronic Hepatitis B Virus (HBV) infection.
    • Further research is required to optimize siRNA sequences for maximum efficacy and minimize off-target effects.
    • Development of efficient hepatotropic nucleic acid delivery methods is crucial for successful clinical application of RNAi therapies for HBV.